Alnair Therapeutics

Alnair Therapeutics is a private, preclinical-stage biotech founded in 2020, pioneering a novel drug delivery platform that targets lactate, a universal metabolite of the Warburg Effect in tumors. Its core technology, the Alnair Lactate-reactive Nanoparticle (ALN), uses a self-immolative cap to release encapsulated drugs specifically in the high-lactate tumor microenvironment, aiming to reduce systemic toxicity and enable dose intensification. The lead program focuses on repurposing cytotoxic chemotherapy for breast, ovarian, and sarcoma cancers, with a pipeline exploring targeted small molecules and immunomodulatory agents. The company is headquartered in Cambridge, Massachusetts, with an additional office in Chicago, Illinois.

Alnair Lactate-reacting Nanoparticle (ALN) platform: A mesoporous silica nanoparticle (MSN) drug carrier sealed with a proprietary, self-immolative cap that reacts to high lactate concentrations in the tumor microenvironment, enabling selective drug release.

Competition includes other companies developing tumor-microenvironment-targeted drug delivery systems (e.g., pH-sensitive nanoparticles, protease-activated prodrugs). Alnair differentiates by directly targeting lactate, a universal metabolic hallmark, rather than surrogate markers. It also competes with developers of new, less toxic chemotherapeutics and targeted agents.